Advertisement

Topics

aap Implantate (AAQ) - Exploring strategic alternatives to add value

12:53 EDT 17 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - aap Implantate: aap Implantate announced its H1 results with a 5% increase in l-f-l sales to €5.4m. This increase was predominantly due to a reported 14% Trauma sales growth in H1 despite Q2 Trauma sales remaining flat versus the previous year’s €2.3m, though still broadly in line with management’s expectations. H1 positives include growth in established markets where aap Implantate has focused initiatives to drive sales (North America +26% and DACH region +10%). Traction in these markets (Europe and the US) remains key to a sustained return to growth.
ISIN: DE0005066609

Original Article: aap Implantate (AAQ) - Exploring strategic alternatives to add value

NEXT ARTICLE

More From BioPortfolio on "aap Implantate (AAQ) - Exploring strategic alternatives to add value"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...